Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston, Mass.
Department of Surgery, Massachusetts General Hospital, Boston, Mass.
J Vasc Surg. 2020 Sep;72(3):886-895.e1. doi: 10.1016/j.jvs.2019.11.028. Epub 2020 Jan 19.
Trials for endovascular aneurysm repair (EVAR) report lower perioperative mortality and morbidity, but also higher costs compared with open repair. However, few studies have examined the subsequent cost of follow-up evaluations and interventions. Therefore, we present the index and 5-year follow-up costs of EVAR from the Endurant Stent Graft System Post Approval Study.
From August 2011 to June 2012, 178 patients were enrolled in the Endurant Stent Graft System Post Approval Study de novo cohort and treated with the Medtronic Endurant stent graft system (Medtronic Vascular, Santa Rosa, Calif), of whom 171 (96%) consented for inclusion in the economic analysis and 177 participated in the quality-of-life (QOL) assessment over a 5-year follow-up period. Cost data for the index and follow-up hospitalizations were tabulated directly from hospital bills and categorized by Uniform Billing codes. Surgeon costs were calculated by Current Procedural Terminology codes for each intervention. Current Procedural Terminology codes were also used to calculate imaging and clinic follow-up reimbursement as surrogate to cost based on year-specific Medicare payment rates. Additionally, we compared aneurysm-related versus nonaneurysm-related subsequent hospitalization costs and report EuroQol 5D QOL dimensions.
The mean hospital cost per person for the index EVAR was $45,304 (interquartile range [IQR], $25,932-$44,784). The largest contributor to the overall cost was operating room supplies, which accounted for 50% of the total cost at a mean of $22,849 per person. One hundred patients had 233 additional post index admission inpatient admissions; however, only 32 readmissions (14%) were aneurysm related, with a median cost of $13,119 (IQR, $4570-$24,153) compared with a nonaneurysm-related median cost of $6609 (IQR, $1244-$26,466). Additionally, 32 patients were admitted a total of 37 times for additional procedures after index admission, of which 14 (38%) were aneurysm-related. The median cost of hospitalization for aneurysm-related subsequent intervention was $22,023 (IQR, $13,177-$47,752), compared with a median nonaneurysm-related subsequent intervention cost of $19,007 (IQR, $8708-$33,301). After the initial 30-day visit, outpatient follow-up imaging reimbursement averaged $550 per person per year ($475 for computed tomography scans, $75 for the abdomen), whereas annual office visits averaged $107 per person per year, for a total follow-up reimbursement of $657 per person per year. There were no significant differences in the five EuroQol 5D QOL dimensions at each follow-up compared with baseline.
Costs associated with index EVAR are driven primarily by cost of operating room supplies, including graft components. Subsequent admissions are largely not aneurysm related; however, cost of aneurysm-related hospitalizations is higher than for nonaneurysm admissions. These data will serve as a baseline for comparison with open repair and other devices.
血管内动脉瘤修复术(EVAR)的试验报告显示围手术期死亡率和发病率较低,但与开放修复相比,成本也较高。然而,很少有研究检查后续随访评估和干预的成本。因此,我们展示了 Endurant 支架移植物系统批准后研究的索引和 5 年随访成本。
从 2011 年 8 月到 2012 年 6 月,178 名患者被纳入 Endurant 支架移植物系统批准后研究的新队列,并使用美敦力 Endurant 支架移植物系统(美敦力血管,加利福尼亚州圣罗莎)进行治疗,其中 171 名(96%)同意纳入经济分析,177 名在 5 年随访期间参加了生活质量(QOL)评估。索引和随访住院的成本数据直接从医院账单中列出,并按统一计费代码进行分类。每个干预的外科医生成本通过当前程序术语代码计算。还使用当前程序术语代码计算成像和诊所随访报销,作为基于特定年份的医疗保险支付率的成本替代。此外,我们比较了与动脉瘤相关的和非动脉瘤相关的后续住院治疗成本,并报告了 EuroQol 5D QOL 维度。
索引 EVAR 的人均医院成本为 45304 美元(四分位距 [IQR],25932-44784 美元)。总体成本的最大贡献者是手术室用品,其占总成本的 50%,人均 22849 美元。100 名患者有 233 次额外的索引后入院住院治疗;然而,只有 32 次再入院(14%)与动脉瘤有关,中位数费用为 13119 美元(IQR,4570-24153 美元),而非动脉瘤相关的中位数费用为 6609 美元(IQR,1244-26466 美元)。此外,32 名患者在索引后共进行了 37 次额外的程序入院,其中 14 次(38%)与动脉瘤有关。与动脉瘤相关的后续干预的中位住院费用为 22023 美元(IQR,13177-47752 美元),而非动脉瘤相关的后续干预的中位费用为 19007 美元(IQR,8708-33301 美元)。初始 30 天就诊后,每年每人的门诊随访成像报销平均为 550 美元(CT 扫描 475 美元,腹部扫描 75 美元),每年每人的办公室就诊平均为 107 美元,每年每人的随访报销总额为 657 美元。与基线相比,在每次随访时,五个 EuroQol 5D QOL 维度均无显著差异。
索引 EVAR 相关成本主要由手术室用品成本驱动,包括移植物组件。随后的入院主要与动脉瘤无关;然而,与动脉瘤相关的住院费用高于非动脉瘤住院费用。这些数据将作为与开放修复和其他设备进行比较的基线。